Search research articles
Contact Us
Filters
Showing results (1-10 of 192) with videos related to
Page
of 20
Sort By:
The Lancet. Oncology
|
April 1, 2021
Relapsed or refractory classical Hodgkin lymphoma: which immunotherapy, and when?
Theodoros P Vassilakopoulos
Seminars in Hematology
|
August 7, 2016
Hodgkin lymphoma: Introduction
Andreas Engert, Theodoros P Vassilakopoulos
Blood
|
April 25, 2024
Thrombocytosis
Athanasios Liaskas, Theodoros P Vassilakopoulos
British Journal of Haematology
|
May 16, 2026
Is universal CAR T-cell referral absolutely required for transplant-ineligible patients with primary refractory or early relapsed DLBCL?
Maria Dimou, Theodoros P Vassilakopoulos
Blood
|
April 22, 2021
Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?
Chrysovalantou Chatzidimitriou, Theodoros P Vassilakopoulos
Seminars in Hematology
|
March 20, 2013
Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years
Theodoros P Vassilakopoulos, Maria K Angelopoulou
Seminars in Hematology
|
August 7, 2016
Treatment of advanced-stage Hodgkin lymphoma
Theodoros P Vassilakopoulos, Peter W M Johnson
Translational Pediatrics
|
February 3, 2016
Omitting or reducing radiotherapy in childhood or adolescence Hodgkin Lymphoma
Theodoros P Vassilakopoulos, Georgios Boutsikas, Vassilios Papadakis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2016
HD2000 Update in Hodgkin Lymphoma-ABVD or BEACOPP?
Theodoros P Vassilakopoulos, Peter W M Johnson
Haematologica
|
November 2, 2015
Comment on "Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial"
Theodoros P Vassilakopoulos, John Apostolidis, Maria K Angelopoulou
Page
of 20
Search research articles
Search
Showing results (1-10 of 192) with videos related to
Sort By:
Page
of 20
The Lancet. Oncology
|
April 1, 2021
Relapsed or refractory classical Hodgkin lymphoma: which immunotherapy, and when?
Theodoros P Vassilakopoulos
Seminars in Hematology
|
August 7, 2016
Hodgkin lymphoma: Introduction
Andreas Engert, Theodoros P Vassilakopoulos
Blood
|
April 25, 2024
Thrombocytosis
Athanasios Liaskas, Theodoros P Vassilakopoulos
British Journal of Haematology
|
May 16, 2026
Is universal CAR T-cell referral absolutely required for transplant-ineligible patients with primary refractory or early relapsed DLBCL?
Maria Dimou, Theodoros P Vassilakopoulos
Blood
|
April 22, 2021
Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?
Chrysovalantou Chatzidimitriou, Theodoros P Vassilakopoulos
Seminars in Hematology
|
March 20, 2013
Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years
Theodoros P Vassilakopoulos, Maria K Angelopoulou
Seminars in Hematology
|
August 7, 2016
Treatment of advanced-stage Hodgkin lymphoma
Theodoros P Vassilakopoulos, Peter W M Johnson
Translational Pediatrics
|
February 3, 2016
Omitting or reducing radiotherapy in childhood or adolescence Hodgkin Lymphoma
Theodoros P Vassilakopoulos, Georgios Boutsikas, Vassilios Papadakis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2016
HD2000 Update in Hodgkin Lymphoma-ABVD or BEACOPP?
Theodoros P Vassilakopoulos, Peter W M Johnson
Haematologica
|
November 2, 2015
Comment on "Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial"
Theodoros P Vassilakopoulos, John Apostolidis, Maria K Angelopoulou
Page
of 20